Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Alexa C. Klimchak, Lauren E. Sedita, Louise R. Rodino-Klapac, Jerry R. Mendell, Craig M. McDonald, Katherine L. Gooch & Daniel C. Malone. (2023) Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States. Journal of Market Access & Health Policy 11:1.
Read now
Read now
Kelsie D. Kracht, Nicole L. Eichorn & Daniel J. Berlau. (2022) Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy. Expert Opinion on Pharmacotherapy 23:15, pages 1701-1710.
Read now
Read now
Omar Sheikh & Toshifumi Yokota. (2021) Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies. Expert Opinion on Investigational Drugs 30:2, pages 167-176.
Read now
Read now
Articles from other publishers (40)
Shahnawaz Amdani, Scott R Auerbach, Neha Bansal, Sharon Chen, Jennifer Conway, Julie Pires Da Silva, Shriprasad R Deshpande, Jessica Hoover, Kimberly Lin, Shelley Miyamoto, Kriti Puri, Jack Price, Joseph Spinner, Rachel White, Joseph W. Rossano, David W. Bearl, Melissa K. Cousino, Perry Catlin, Nicolas Corral Hidalgo, Justin Godown, Paul Kantor, Daniele Masarone, David M. Peng, Kelly E. Rea, Kurt Schumacher, Robert Shaddy, Erin Shea, Henry Valora Tapia, Nishma Valikodath, Farhan Zafar & Daphne Hsu. (2023) Research gaps in pediatric heart failure: defining the gaps and then closing them over the next decade.. Journal of Cardiac Failure.
Crossref
Crossref
Christopher Chan, Kathryn K. Harris, Sergei Zolotukhin & Geoffrey D. Keeler. (2023) Rational Design of AAV-rh74, AAV3B, and AAV8 with Limited Liver Targeting. Viruses 15:11, pages 2168.
Crossref
Crossref
Damon Asher, Daisy Dai, Alexa C. Klimchak, Lauren E. Sedita, Katherine L. Gooch & Louise Rodino-Klapac. (2023) Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec. Molecular Therapy - Methods & Clinical Development 30, pages 474-483.
Crossref
Crossref
Sheridan M. Hoy. (2023) Delandistrogene Moxeparvovec: First Approval. Drugs 83:14, pages 1323-1329.
Crossref
Crossref
James Zengel, Yu Xin Wang, Jai Woong Seo, Ke Ning, James N. Hamilton, Bo Wu, Marina Raie, Colin Holbrook, Shiqi Su, Derek R. Clements, Sirika Pillay, Andreas S. Puschnik, Monte M. Winslow, Juliana Idoyaga, Claude M. Nagamine, Yang Sun, Vinit B. Mahajan, Katherine W. Ferrara, Helen M. Blau & Jan E. Carette. (2023) Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression. Nature Methods 20:7, pages 1070-1081.
Crossref
Crossref
D. Bradley Welling. (2023) Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons. Otolaryngologic Clinics of North America 56:3, pages 543-556.
Crossref
Crossref
Annemieke Aartsma-Rus, Liesbeth De Waele, Saskia Houwen-Opstal, Janbernd Kirschner, Yvonne D. Krom, Eugenio Mercuri, Erik H. Niks, Volker Straub, Hermine A. van Duyvenvoorde & Elizabeth Vroom. (2023) The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience. Journal of Neuromuscular Diseases 10:3, pages 315-325.
Crossref
Crossref
Francesco ChemelloEric N. OlsonRhonda Bassel-Duby. (2023) CRISPR-Editing Therapy for Duchenne Muscular Dystrophy. Human Gene Therapy 34:9-10, pages 379-387.
Crossref
Crossref
Karen AnthonyPierpaolo AlaFrancesco CatapanoJinhong MengJoana DomingosMark PerryValeria RicottiKate MareshLauren C. PhillipsLaurent ServaisAndreea M. SeferianSilvana De LuciaImelda de GrootYvonne D. KromJ.G.M. VerschuurenErik H. NiksVolker StraubMichela GuglieriThomas VoitJennifer Morgan & Francesco Muntoni. (2023) T Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy. Human Gene Therapy 34:9-10, pages 439-448.
Crossref
Crossref
Hildegund C. J. Ertl. (2023) Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression. Drugs 83:4, pages 287-298.
Crossref
Crossref
Leonit Kiriaev, Cory W. Baumann & Angus Lindsay. (2023) Eccentric contraction-induced strength loss in dystrophin-deficient muscle: Preparations, protocols, and mechanisms. Journal of General Physiology 155:2.
Crossref
Crossref
Senthilkumar Preethy, Naoki Yamamoto, Shiro Osaza, Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Masaru Iwasaki & Samuel JK Abraham. (2023) Re-examination of therapeutic management of muscular dystrophies using a vascular smooth muscle-centered approach. Journal of Smooth Muscle Research 59:0, pages 67-80.
Crossref
Crossref
Natalie L. Goedeker, Sachi D. Dharia, Danielle A. Griffin, Jesantha Coy, Todd Truesdale, Rajan Parikh, Kasen Whitehouse, Sourav Santra, Damon R. Asher & Craig M. Zaidman. (2023) Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy. Therapeutic Advances in Neurological Disorders 16, pages 175628642211497.
Crossref
Crossref
Sadegh Shojaei Baghini, Zhanna R. Gardanova, Saeme Azizi Hassan Abadi, Burhan Abdullah Zaman, Ahmet İlhan, Navid Shomali, Ali Adili, Roozbeh Moghaddar & Amirhossein Fakhre Yaseri. (2022) CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool. Cellular & Molecular Biology Letters 27:1.
Crossref
Crossref
Piyali Guhathakurta, Anna L. Carter, Andrew R. Thompson, Dillon Kurila, Jeffrey LaFrence, Li Zhang, Jake R. Trask, Bri Vanderheyden, Joseph M. Muretta, James M. Ervasti & David D. Thomas. (2022) Enhancing interaction of actin and actin-binding domain 1 of dystrophin with modulators: Toward improved gene therapy for Duchenne muscular dystrophy. Journal of Biological Chemistry 298:12, pages 102675.
Crossref
Crossref
Lyubava Belova, Alexander Lavrov & Svetlana Smirnikhina. (2022) Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities. BioEssays 44:9.
Crossref
Crossref
Francesco Canonico, Maila Chirivi, Fabio Maiullari, Marika Milan, Roberto Rizzi, Alessandra Arcudi, Mattia Galli, Marika Pane, Aoife Gowran, Giulio Pompilio, Eugenio Mercuri, Filippo Crea, Claudia Bearzi & Domenico D’Amario. (2022) Focus on the road to modelling cardiomyopathy in muscular dystrophy. Cardiovascular Research 118:8, pages 1872-1884.
Crossref
Crossref
Andreas Ziegler. (2022) Präzisionsmedizin in der Kinderneurologie am Beispiel der neuen TherapienPrecision medicine in pediatric neurology exemplified by the new treatment forms. Der Nervenarzt 93:2, pages 122-134.
Crossref
Crossref
Yasunari Matsuzaka, Yukihiko Hirai, Kazuo Hashido & Takashi Okada. (2022) Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via nSMase2/Smpd3, Satellite, and Immune Cells in Duchenne Muscular Dystrophy. International Journal of Molecular Sciences 23:3, pages 1551.
Crossref
Crossref
Tomoki Hirunagi, Kentaro Sahashi, Katherine G. Meilleur & Masahisa Katsuno. (2022) Nucleic Acid-Based Therapeutic Approach for Spinal and Bulbar Muscular Atrophy and Related Neurological Disorders. Genes 13:1, pages 109.
Crossref
Crossref
Luiza Amara Maciel Braga, Carlos Gilbert Conte Filho & Fabio Batista Mota. (2022) Future of genetic therapies for rare genetic diseases: what to expect for the next 15 years?. Therapeutic Advances in Rare Disease 3, pages 263300402211008.
Crossref
Crossref
Jennifer Morgan & Francesco Muntoni. (2021) Changes in Myonuclear Number During Postnatal Growth – Implications for AAV Gene Therapy for Muscular Dystrophy. Journal of Neuromuscular Diseases 8:s2, pages S317-S324.
Crossref
Crossref
Sadegh Shojaei Baghini, Zhanna R. Gardanova, Angelina Olegovna Zekiy, Navid Shomali, Foad Tosan & Mostafa Jarahian. (2021) Optimizing sgRNA to Improve CRISPR/Cas9 Knockout Efficiency: Special Focus on Human and Animal Cell. Frontiers in Bioengineering and Biotechnology 9.
Crossref
Crossref
Elizabeth A. Kichula, Crystal M. Proud, Michelle A. Farrar, Jennifer M. Kwon, Kayoko Saito, Isabelle Desguerre & Hugh J. McMillan. (2021) Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle & Nerve 64:4, pages 413-427.
Crossref
Crossref
Elena Abati, Emanuele Sclarandi, Giacomo Pietro Comi, Valeria Parente & Stefania Corti. (2021) Perspectives on hiPSC-Derived Muscle Cells as Drug Discovery Models for Muscular Dystrophies. International Journal of Molecular Sciences 22:17, pages 9630.
Crossref
Crossref
Tracey Willis. (2021) Recent advances in the treatment of Duchenne muscular dystrophy. Paediatrics and Child Health 31:9, pages 359-363.
Crossref
Crossref
Shanshan Yao, Zihao Chen, Yuanyuan Yu, Ning Zhang, Hewen Jiang, Ge Zhang, Zongkang Zhang & Baoting Zhang. (2021) Current Pharmacological Strategies for Duchenne Muscular Dystrophy. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Tomoko Lee, Sachi Tokunaga, Naoko Taniguchi, Maiko Misaki, Hideki Shimomura, Ichizo Nishino, Kyoko Itoh & Yasuhiro Takeshima. (2021) Underlying diseases in sporadic presentation of high creatine kinase levels in girls. Clinica Chimica Acta 519, pages 198-203.
Crossref
Crossref
Dimitra G. Georganopoulou, Vasilis G. Moisiadis, Firhan A. Malik, Ali Mohajer, Tanya M. Dashevsky, Shirley T. Wuu & Chih-Kao Hu. (2021) A Journey with LGMD: From Protein Abnormalities to Patient Impact. The Protein Journal 40:4, pages 466-488.
Crossref
Crossref
Omar Sheikh & Toshifumi Yokota. (2021) Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy. BioDrugs 35:4, pages 389-399.
Crossref
Crossref
Eric N. Olson. (2021) Toward the correction of muscular dystrophy by gene editing. Proceedings of the National Academy of Sciences 118:22.
Crossref
Crossref
Poh Kuan Wong, Fook Choe Cheah, Saiful Effendi Syafruddin, M. Aiman Mohtar, Norazrina Azmi, Pei Yuen Ng & Eng Wee Chua. (2021) CRISPR Gene-Editing Models Geared Toward Therapy for Hereditary and Developmental Neurological Disorders. Frontiers in Pediatrics 9.
Crossref
Crossref
Jerry R. Mendell, Samiah A. Al-Zaidy, Louise R. Rodino-Klapac, Kimberly Goodspeed, Steven J. Gray, Christine N. Kay, Sanford L. Boye, Shannon E. Boye, Lindsey A. George, Stephanie Salabarria, Manuela Corti, Barry J. Byrne & Jacques P. Tremblay. (2021) Current Clinical Applications of In Vivo Gene Therapy with AAVs. Molecular Therapy 29:2, pages 464-488.
Crossref
Crossref
Robert D. Bell. 2022. Physiology, Pharmacology and Pathology of the Blood-Brain Barrier. Physiology, Pharmacology and Pathology of the Blood-Brain Barrier
83
95
.
Elisabeth R. Barton, Christina A. Pacak, Whitney L. Stoppel & Peter B. Kang. (2020) The ties that bind: functional clusters in limb-girdle muscular dystrophy. Skeletal Muscle 10:1.
Crossref
Crossref
Laurine Buscara, David-Alexandre Gross & Nathalie Daniele. (2020) Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back. Journal of Personalized Medicine 10:4, pages 258.
Crossref
Crossref
Sean Y Ng & Vladimir Ljubicic. (2020) Recent insights into neuromuscular junction biology in Duchenne muscular dystrophy: Impacts, challenges, and opportunities. EBioMedicine 61, pages 103032.
Crossref
Crossref
Claudia Nuñez-Peralta, Jorge Alonso-Pérez & Jordi Díaz-Manera. (2020) The increasing role of muscle MRI to monitor changes over time in untreated and treated muscle diseases. Current Opinion in Neurology 33:5, pages 611-620.
Crossref
Crossref
Chengmei Sun, Luoan Shen, Zheng Zhang & Xin Xie. (2020) Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update. Genes 11:8, pages 837.
Crossref
Crossref
Francesco Chemello, Rhonda Bassel-Duby & Eric N. Olson. (2020) Correction of muscular dystrophies by CRISPR gene editing. Journal of Clinical Investigation 130:6, pages 2766-2776.
Crossref
Crossref